This review concluded that, compared to coronary artery bypass graft (CABG), drug-eluting stents were associated with fewer periprocedural risks, but evidence suggested that drug-eluting stents were inferior to CABG in terms of postprocedural myocardial infarction, repeat revascularisation and 12-month combined outcome. Concerns about data quality mean that the authors conclusions should be treated with caution.
Study selection
Studies that compared drug-eluting stents to CABG in people with coronary artery disease were eligible for inclusion.
In the included studies, where reported, mean ages ranged from 58 to 72 years in the drug-eluting stents groups and 61 to 70 years in the CABG groups. Mean ejection fraction ranged from 28% to 62% in the drug-eluting stents group and 27% to 62% in the CABG group. Participants had single or multivessel disease and some had diabetes or left ventricular dysfunction. Some of the CABG procedures were off pump (OPCAB). The outcomes reported were all-cause mortality, all-cause stroke, myocardial infarction, repeat revascularisation and major adverse cardiovascular and cerebrovascular events (MACCE). Follow-up ranged from six to 36 months. Studies were performed between 1997 and 2007.
It appeared that two authors independently selected studies for inclusion. Discrepancies were resolved by discussion and consensus with a third author.
Assessment of study quality
The numbers of participants lost to follow-up was reported. No other details of any quality assessment were given.
Data extraction
Data were extracted in order to calculate relative risks (RR) and 95% confidence intervals (CI).
It appeared that data were extracted by two authors independently. Discrepancies were resolved by discussion and consensus with a third author.
Methods of synthesis
Pooled relative risks and 95% CI were calculated using fixed-effect and random-effects models. Results for the randomeffects model were reported. Statistical heterogeneity was assessed using Χ² and Ι². Subgroup analyses were performed based on those with multivessel disease and those with OPCAB.
